SignatureFD’s Neurogene NGNE Stock Holding History

SignatureFD’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22	Closed	-$503	–	3406
2024 Q4	$503	Hold	22	–	–	﹤0.01%	3140
2024 Q3	$923	Buy	+22	New	+$853	﹤0.01%	3012
2021 Q4	–	Sell	-24	Closed	-$4K	–	3212
2021 Q3	$4K	Buy	+24	New	+$3.67K	﹤0.01%	2447

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

SignatureFD's NGNE Position: Q1 2025 in Review

SignatureFD sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 22 shares — an estimated $503 sold.

SignatureFD first reported a position in NGNE in Q3 2021 and held it in 3 quarters. The position peaked at $4K in Q3 2021. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

SignatureFD reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
SignatureFD sold 22 Neurogene shares in Q1 2025, an estimated $503.
SignatureFD first reported a position in Neurogene in Q3 2021 and held it in 3 quarters.
SignatureFD's Neurogene position peaked at $4K in Q3 2021.
85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on SignatureFD's 13F filing for Q1 2025, filed 2 May 2025.